NASDAQ-NMS:IMAB

I-Mab Receives Top Rankings in Five Categories by Institutional Investor

Retrieved on: 
Thursday, June 23, 2022
WeChat, IR, Lishui, GMP, Honor of Kings, Company, U.S. Securities and Exchange Commission, Leadership, Research, Forward-looking statement, LinkedIn, Institutional Investor (magazine), Twitter, Patient, Institution, ESG, Institutional Investor, Retail, Fine chemical, Small

The awards recognize I-Mab's continued strong leadership, corporate governance, ESG strategy, and investor relations capabilities.

Key Points: 
  • The awards recognize I-Mab's continued strong leadership, corporate governance, ESG strategy, and investor relations capabilities.
  • I-Mab was recognized in the "Honored Companies," "Best CEO," "Best CFO," "Best IR Professional," "Best IR Program," and "Best ESG" categories.
  • The ranking by Institutional Investor signifies capital market recognition of the Company's continued leadership in innovation and excellence in corporate governance.
  • The details of I-Mab's rankings are:
    The Company is named the "the Honored Company" in Core Asia, Mainland China and Small & Midcap results.

I-Mab Partner MorphoSys Announces New License Agreements for Felzartamab and TJ210

Retrieved on: 
Wednesday, June 15, 2022
WeChat, Cancer, Intellectual property, NDA, Lishui, GMP, COVID-19, Safety, Neoplasm, Risk, Technology, Economics, Neutrophil, CD38, ADCP, Company, U.S. Securities and Exchange Commission, Inflammation, Forward-looking statement, Private Securities Litigation Reform Act, LinkedIn, Antigen, MDSC, ADCC, Degenerative disease, Annual report, Immune system, NASDAQ, Myeloid-derived suppressor cell, SEC, MM, Platinum, C5a, Partnership, Twitter, FSE, Patient, Autoimmunity, Terminology, Receptor (biochemistry), CDC, Form 20-F, Pharmaceutical industry, Vaccine, Greater China, MorphoSys

Currently I-Mab is developing and commercializing felzartamab in Greater China and TJ210 in Greater China and South Korea.

Key Points: 
  • Currently I-Mab is developing and commercializing felzartamab in Greater China and TJ210 in Greater China and South Korea.
  • Under the terms of the new agreements, HIBio will obtain exclusive rights to develop and commercialize felzartamab and TJ210 across all indications worldwide, excluding Greater China for felzartamab and Greater China and South Korea for TJ210.
  • We are excited and look forward to working together with MorphoSys and HIBio to advance clinical development and commercialization of felzartamab and TJ210," said Dr. Andrew Zhu, President of I-Mab.
  • MorphoSys and I-Mab entered into an exclusive strategic collaboration and licensing agreement to develop and commercialize TJ210 in November 2018.

I-Mab Partner MorphoSys Announces New License Agreements for Felzartamab and TJ210

Retrieved on: 
Wednesday, June 15, 2022
WeChat, Cancer, Intellectual property, NDA, Lishui, GMP, COVID-19, Safety, Neoplasm, Risk, Technology, Neutrophil, CD38, ADCP, Company, U.S. Securities and Exchange Commission, Inflammation, Forward-looking statement, Private Securities Litigation Reform Act, LinkedIn, Antigen, MDSC, ADCC, Degenerative disease, Annual report, Immune system, NASDAQ, Myeloid-derived suppressor cell, SEC, MM, Platinum, C5a, Partnership, Twitter, FSE, Patient, Autoimmunity, Terminology, Receptor (biochemistry), CDC, Form 20-F, Pharmaceutical industry, Vaccine, Greater China, MorphoSys

Currently I-Mab is developing and commercializing felzartamab in Greater China and TJ210 in Greater China and South Korea.

Key Points: 
  • Currently I-Mab is developing and commercializing felzartamab in Greater China and TJ210 in Greater China and South Korea.
  • Under the terms of the new agreements, HIBio will obtain exclusive rights to develop and commercialize felzartamab and TJ210 across all indications worldwide, excluding Greater China for felzartamab and Greater China and South Korea for TJ210.
  • We are excited and look forward to working together with MorphoSys and HIBio to advance clinical development and commercialization of felzartamab and TJ210," said Dr. Andrew Zhu, President of I-Mab.
  • MorphoSys and I-Mab entered into an exclusive strategic collaboration and licensing agreement to develop and commercialize TJ210 in November 2018.

I-Mab Announces Appointments of Richard Yeh as Chief Operating Officer and John Hayslip as Chief Medical Officer

Retrieved on: 
Thursday, April 28, 2022

SHANGHAI and GAITHERSBURG, MD, April 28, 2022 /PRNewswire/ --I-Mab ("I-Mab" or the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, announced today the appointments of Mr. Richard Yeh as Chief Operating Officer and Dr. John Hayslip as Chief Medical Officer. The two key appointments add greater depth and breadth of industry experience to the Company's leading management team, further accelerating its global ambition in innovation and to become a specialty global biopharmaceutical company.

Key Points: 
  • "Mr. Yeh will play an integral role in further enhancing our global investor network and strengthening our global business partnerships.
  • While Dr.Hayslipwill apply his nearly two decades of clinical research expertise inoncologyto advancing our globally competitive pipeline of innovative assets."
  • Before joining I-Mab, Mr. Yeh wasChief Financial Officer and Head of Strategic Operations atAbbiskoTherapeutics(HKEX: 2256), overseeing financial transactions, strategic planning, financial & accounting reports, risk management and fundraising.
  • Dr.Hayslipreceived his medical degree from Northeast Ohio Medical University and a master's degree in Clinical Research from the Medical University of South Carolina.

I-Mab to Report Full Year 2021 Financial Results and Provide Corporate Update on March 29, 2022

Retrieved on: 
Friday, March 18, 2022
Lishui, Company, WeChat, LinkedIn, GMP, Degenerative disease, Twitter, Patient, EST, Pharmaceutical industry, MD

The Company's mission is to bring transformational medicines to patients around the world through innovation.

Key Points: 
  • The Company's mission is to bring transformational medicines to patients around the world through innovation.
  • The Company is progressing from a clinical-stage biotech company into a fully integrated global biopharmaceutical company with cutting-edge R&D capabilities, a world-class GMP manufacturing facility, and commercial capability.
  • I-Mab has established its global footprint in Shanghai (headquarters), Beijing, Hangzhou, Guangzhou, Lishui and Hong Kong in China, and Maryland and San Diego in the United States.
  • For more information, please visit http://ir.i-mabbiopharma.com and follow I-Mab on LinkedIn , Twitter , and WeChat .

I-Mab Announces Multiple Presentations at the 2022 American Association for Cancer Research (AACR) Annual Meeting

Retrieved on: 
Wednesday, March 9, 2022
Safety, GMP, Twitter, Form 20-F, Annual report, Private Securities Litigation Reform Act, Risk, Company, CLDN6, Antibody, Immune system, U.S. Securities and Exchange Commission, Cancer, Lishui, NDA, Degenerative disease, Intellectual property, CD45, CD8, Toxicity, Patient, WeChat, Enoblituzumab, Neoplasm, Technology, COVID-19, B7, Liver, B7-H3, FC, LinkedIn, Vaccine, Pharmaceutical industry

Taken together, these data support further development of TJ-C64B towards clinical development subsequently.

Key Points: 
  • Taken together, these data support further development of TJ-C64B towards clinical development subsequently.
  • Enoblituzumab is an investigational Fc-optimized monoclonal antibody that targets B7-H3, a member of the B7 family of immune regulator proteins.
  • B7-H3 is widely expressed by many different tumor types and may play a key role in regulating the immune response to various types of cancer.
  • TJ-C64B is a bispecific antibody simultaneously targeting tumor associated antigen Claudin 6 (CLDN6) and costimulatory molecule 4-1BB for CLDN6+ tumor treatment.

I-Mab Receives FDA Orphan Drug Designation for its Novel Claudin 18.2 x 4-1BB Bispecific Antibody TJ-CD4B for the Treatment of Gastric Cancer

Retrieved on: 
Thursday, March 3, 2022
Private Securities Litigation Reform Act, NDA, Stomach, Lishui, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Toxicity, American Cancer Society Cancer Action Network, Annual report, Patient, Death, Twitter, Food, Safety, U.S. Securities and Exchange Commission, Orphan drug, LinkedIn, Stomach cancer, FDA, Person, Company, Cancer, COVID-19, GMP, Trial of the century, American Cancer Society, Degenerative disease, Form 20-F, Risk, Technology, Mortality, Liver, Intellectual property, WeChat, Incidence, Antibody, Pharmaceutical industry, Vaccine, Medical imaging

"The Orphan Drug Designation underscores the FDA's recognition of TJ-CD4B's potential promise as a novel therapy for gastric cancer and other related cancers," said Dr. Andrew Zhu, President of I-Mab.

Key Points: 
  • "The Orphan Drug Designation underscores the FDA's recognition of TJ-CD4B's potential promise as a novel therapy for gastric cancer and other related cancers," said Dr. Andrew Zhu, President of I-Mab.
  • "TJ-CD4B is designed to work through a novel mechanism of action and is being tested in cancer patients.
  • TJ-CD4B is the first clinical-stage bispecific antibody that binds to Claudin 18.2 (CLDN18.2)-expressing cancer cells and co-stimulatory molecule 4-1BB on T cells to exert a tumor-killing effect.
  • Gastric cancer is the fifth most common cancer and third most common cause of death due to cancers globally.